Repligen | RGEN - Assets


Repligen reported $2.95B in Assets for its fiscal quarter ending in June of 2026.





Assets Change Date
Agilent USD 13.07B 252M Mar/2026
Align Technology USD 6.42B 103.41M Jun/2026
Bio Techne USD 2.55B 27.9M Mar/2026
BioMarin Pharmaceutical USD 8.59B 996.99M Mar/2026
Bristol-Myers Squibb USD 87.63B 1.16B Jun/2026
Bruker USD 6.05B 77.8M Jun/2026
Charles River Laboratories USD 7.53B 198.16M Jun/2026
Danaher USD 92.37B 8.82B Jun/2026
Dentsply International USD 5.23B 200M Mar/2026
General Electric Aerospace USD 127.67B 773M Jun/2026
Henry Schein USD 11.38B 77M Jun/2026
Illumina USD 6.65B 91M Jun/2026
IQVIA Holdings USD 29.88B 206M Jun/2026
Mettler Toledo International USD 3.67B 2.03M Jun/2026
Myriad Genetics USD 638.9M 34.8M Jun/2026
OraSure Technologies USD 379.17M 24M Mar/2026
Pacific Biosciences Of California USD 782.36M 1.72M Mar/2026
Pfizer USD 201.13B 6.49B Jun/2026
Repligen USD 2.95B 19.41M Jun/2026
Revvity USD 12.05B 49.24M Jun/2026
Standard Biotools USD 639.11M 71.36M Mar/2026
Thermo Fisher Scientific USD 113.17B 107M Jun/2026
Waters USD 24.75B 220M Jun/2026
West Pharmaceutical Services USD 4.08B 33.4M Jun/2026